Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BNT113

Vaccine (mRNA vaccine) · Immune activation, directed at HPV-16 E6 oncoprotein and HPV-16 E7 oncoprotein · developed by BioNTech

Phase 2/3 Most advanced trial
BNTX Developer
1 Registered trials

What is BNT113?

BNT113 is an RNA-lipoplex cancer vaccine containing messenger RNA encoding the human papillomavirus type 16 E6 and E7 oncoproteins, encapsulated in liposomes. After uptake by antigen-presenting cells, the expressed antigens are presented to the immune system to induce CD8+ and CD4+ T-cell responses against HPV16 E6 and E7, and it is studied in HPV16-positive head and neck squamous cell carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (mRNA vaccine)
Targets
HPV-16 E6 oncoprotein (antigen), HPV-16 E7 oncoprotein (antigen)
Mechanism
Immune activation, directed at HPV-16 E6 oncoprotein and HPV-16 E7 oncoprotein
Pathways
CD8+ and CD4+ T-cell responses, antigen presentation via HLA
Therapy area
Oncology
Developer
BioNTech SE (BNTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04534205 Phase 2/3 Unresectable Head and Neck Squamous Cell Carcinoma Active not recruiting BNTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Head and Neck CancerRecurrent Head and Neck CancerUnresectable Head and Neck Squamous Cell Carcinoma

More from BioNTech

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BNTX page.

Follow BNTX, the company behind BNT113

See BNTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BNTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.